rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ali Behbahani

Director

Company insider

Files Form 4 as: Director, Black Diamond Therapeutics; Director, CRISPR Therapeutics AG; Director and 10% owner, Monte Rosa Therapeutics; Director, Nkarta; Director and 10% owner, Korro Bio; Director, Arcellx; Director and 10% owner, SpyGlass Pharma; Director and 10% owner, NeueHealth.

Every Form 4 they filed

In numbers

Trades disclosed
335
Buys
21
Sells
9
Bought
$233.5M
Sold
$3.0M
Companies
22
Companies where not an officer
22
First trade
5 Nov 2014
Last trade
18 Sep 2026
Last filed
21 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
BDTX Black Diamond TherapeuticsDirector · Biotechnology · last 18 Sep 20262 buys · 0 sells
CRSP CRISPR Therapeutics AGDirector · Genomics & Gene Editing · last 17 Sep 20260 buys · 1 sell
GLUE Monte Rosa TherapeuticsDirector, 10% owner · Biotechnology · last 1 Jul 20261 buy · 0 sells
KRRO Korro BioDirector, 10% owner · Biotechnology · last 10 Jun 20260 buys · 0 sells
NKTX NkartaDirector · Biotechnology · last 10 Jun 20260 buys · 0 sells
ArcellxDirector · Biotechnology · last 28 Apr 20260 buys · 0 sells
SGP SpyGlass PharmaDirector, 10% owner · Medical Devices · last 9 Feb 20261 buy · 0 sells
NeueHealthDirector, 10% owner · last 2 Oct 20251 buy · 1 sell
Adaptimmune TherapeuticsDirector · last 18 Aug 20252 buys · 2 sells
TRVI Trevi Therapeutics10% owner · Biotechnology · last 17 Apr 20253 buys · 1 sell
MBX MBX Biosciences10% owner · Biotechnology · last 16 Sep 20241 buy · 0 sells
CVRX CVRxDirector · Medical Devices · last 4 Jun 20240 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
201Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
18 Sep 2026filed 21 Sep 2026BDTX Black Diamond TherapeuticsBiotechnologySEC FORM 4 Code A$15K7,707 at $1.93filing
18 Sep 2026filed 21 Sep 2026BDTX Black Diamond TherapeuticsBiotechnologySEC FORM 4 Code A$15K7,707 at $1.93filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Code M$420K30,000 at $14.00filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Sold$781K13,679 at $57.09filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene EditingSEC FORM 4 Code M—30,000 at $0.00filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene EditingSEC FORM 4 Code M—30,000 at $0.00filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Code M$420K30,000 at $14.00filing
17 Sep 2026filed 21 Sep 2026CRSP CRISPR Therapeutics AGGenomics & Gene EditingSEC FORM 4 Sold$781K13,679 at $57.09filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—1,000,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—15,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—15,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—1,000,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—15,000 at $0.00filing
1 Jul 2026filed 6 Jul 2026GLUE Monte Rosa TherapeuticsBiotechnologySEC FORM 4 Code J—15,000 at $0.00filing
26 Jun 2026filed 29 Jun 2026BDTX Black Diamond Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
26 Jun 2026filed 29 Jun 2026BDTX Black Diamond Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
19 Jun 2026filed 22 Jun 2026BDTX Black Diamond TherapeuticsBiotechnologySEC FORM 4 Code A$15K8,961 at $1.66filing
19 Jun 2026filed 22 Jun 2026BDTX Black Diamond TherapeuticsBiotechnologySEC FORM 4 Code A$15K8,961 at $1.66filing
11 Jun 2026filed 12 Jun 2026GLUE Monte Rosa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—25,800 at $0.00filing
11 Jun 2026filed 12 Jun 2026GLUE Monte Rosa Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—25,800 at $0.00filing

Sectors

Health Care13
Not placed17

Buys in green, sells in red, by the company’s sector.

Related people

Simeon GeorgeDirector · Director at CRISPR Therapeutics AG, filing Form 4 there in the last year
James R. KasingerGeneral Counsel and Secretary · General Counsel and Secretary at CRISPR Therapeutics AG, filing Form 4 there in the last year
Samarth KulkarniChief Executive Officer · Chief Executive Officer at CRISPR Therapeutics AG, filing Form 4 there in the last year
Matthew BowenPrincipal Accounting Officer · Principal Accounting Officer at Monte Rosa Therapeutics, filing Form 4 there in the last year
Prakash RamanDirector · Director at Black Diamond Therapeutics, filing Form 4 there in the last year
Michael Thomas HeffernanDirector · Also traded TRVI in the last 90 days
Eric BjerkholtChief Financial Officer · Also traded MIRM in the last 90 days
Jolanda HoweSVP, Global Controller · Also traded MIRM in the last 90 days